Health Condition 1: H046- Other changes of lacrimal passages
Conditions
Interventions
None listed
Sponsors
Dr Bhanu Ahirwar
Eligibility
Inclusion criteria
Inclusion criteria: a) Patients of either gender aged between 12 to 65 years. b) Patients having minimum three symptoms of Computer Vision Syndrome (Eye strain and fatigue, Headache, blurred vision, dry and irritated eyes, double vision, redness of eyes, burning eyes, excessive tearing and photophobia). c) Minimum 3 hours daily exposure to any type of Video Display Terminals (VDT) for 1 year. d) Patients able and willing to provide written informed consent. e) No expectation that subject will be moving out of the area of the study center during the study period.
Exclusion criteria
Exclusion criteria: a) Known allergy to any eye drops. b) Ocular therapies other than artificial tears. c) Patients having current ocular infection, laser in situ keratomileusis (LASIK) in the last 3 months, active ocular allergy, contact lens wearer, Meibomian gland dysfunction (MGD) over grade 2 (the grade is according to the report of the International Workshop on MGD in 2011), severe blepharitis or obvious inflammation of the eyelid margin, which in the judgment of the investigator may interfere with the interpretation of the study results. d) Patients having herpetic eye disease, diabetes, liver diseases, HIV and Hepatitis B and C. e) Systemic (tetracycline s and corticosteroids) or topical medications (other than artificial tear supplements) that could affect tear film or meibomian gland functions will be discontinued prior to intervention. However, patients will be instructed not to use artificial tear preparations, 2 hours prior to testing. f) Pregnancy or lactating mothers. g) Uncontrolled systemic disease. h) Hypersensitivity or intolerance to study drugs (intervention or control). i) Active participation in any type of intervention study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean change from baseline in subjective dry eye symptoms(DESS) and Ocular Surface Disease Index (OSDI) score at the follow-up and end of treatment visit. Timepoint: day0 day15 day30 day45 day60 | — |
Secondary
| Measure | Time frame |
|---|---|
| Mean change in Schirmer test value (tear production) at the follow-up & end of treatment visit compared with baseline. Mean change in the Tear Break Up Time (TBUT) (measure of tear film stability) at the followup & end of treatment visit compared with baseline. The tolerability & safety of Ayurvedic intervention (Yastimadhwadi ashchyotana).Timepoint: day0 day15 day30 day45 day60 | — |
Countries
India
Contacts
Public ContactDr Bhanu Ahirwar
Government Ayurvedic Collage and Hospital Kadamkuan Patna Bihar
Outcome results
None listed